Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
2(11%)
Results Posted
15%(2 trials)

Phase Distribution

Ph phase_1
2
11%
Ph phase_4
2
11%
Ph phase_2
8
44%
Ph not_applicable
1
6%
Ph phase_3
4
22%

Phase Distribution

2

Early Stage

8

Mid Stage

6

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
8(47.1%)
Phase 3Large-scale testing
4(23.5%)
Phase 4Post-market surveillance
2(11.8%)
N/ANon-phased studies
1(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(13)
Other(3)

Detailed Status

Completed13
unknown3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (11.8%)
Phase 28 (47.1%)
Phase 34 (23.5%)
Phase 42 (11.8%)
N/A1 (5.9%)

Trials by Status

completed1372%
active_not_recruiting16%
unknown317%
recruiting16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT04024163Phase 3

Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease

Active Not Recruiting
NCT05523596Phase 1

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

Completed
NCT03672487Phase 3

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Completed
NCT06632600Phase 2

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Recruiting
NCT03981523Phase 2

New Therapies and Biomarkers for Chagas Infection

Completed
NCT03191162Phase 2

Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

Completed
NCT00123916Phase 3

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

Completed
NCT03892213Phase 1

Pharmacokinetic Drug-Drug Interaction Study

Completed
NCT01377480Phase 2

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

Completed
NCT01678599Phase 4

Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease

Completed
NCT03378661Phase 2

BENDITA BEnznidazole New Doses Improved Treatment and Associations

Unknown
NCT02369978Phase 2

CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)

Unknown
NCT01755377

New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

Completed
NCT01755403Phase 4

Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease

Completed
NCT02386358Phase 3

Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial

Completed
NCT01162967Phase 2

Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

Completed
NCT01489228Phase 2

Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease

Unknown
NCT00699387Not Applicable

Population Pharmacokinetics of Benznidazole in Children With Chagas Disease

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18